Mark Hamelburg is a member of Sonnenschein’s Health Care Group. Mr. Hamelburg has almost 20 years of health law experience in a variety of settings and specialties. Mr. Hamelburg’s primary focus is on the Medicare Prescription Drug and Medicare Advantage programs. Prior to joining Sonnenschein in 2009, Mr. Hamelburg served as Director of the Medicare Part C and Part D Analysis Group in the Office of Legislation at the Centers for Medicare & Medicaid Services (CMS) in the U.S. Department of Health & Human Services (HHS). In this capacity, he focused on legislative and regulatory matters involving the Medicare Advantage and Prescription D programs and other issues involving private health insurance. This focus included development and analyses of various legislative and regulatory proposals, technical assistance to Congressional staff, preparation of agency witnesses for testimony and strategic planning on a range of issues. (This is me - Update Profile)
Opinions and analyses expressed in GLG News are solely those of the author. See the Terms of Use for details.
Mark Hamelburg has not published any GLG News Analyses.
Mark Hamelburg is not a member of any GLG Study Groups.
Mark Hamelburg has not participated in any GLG Live Meetings.
View all GLG Live Meetings in Legal, Economic & Regulatory Affairs